AstraZeneca buys lung drug firm Pearl for up to $1.15 bln
LONDON, June 10
LONDON, June 10 (Reuters) - AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.15 billion as Britain's second biggest drugmaker steps up a drive to rebuild its product pipeline via deal-making.
AstraZeneca said on Monday it would pay $560 million upfront, plus up to $450 million if certain development milestones are hit and sales-related payments of up to a further $140 million.
Pearl's lead product, PT003, is a fixed dose combination of formoterol fumarate, a long-acting beta-2-agonist (LABA) and glycopyrrolate, a long-acting muscarinic antagonist (LAMA). It is in final-stage Phase III clinical trials.
- Atheists face death in 13 countries, global discrimination: study
- Mandela signer hits back: I'm sign language champion |
- Missouri executes man for killing good Samaritan motorist in 1994
- Focus turns to Thai military, anti-government protesters tell them to pick sides |
- Google executives' planes saved millions in costs due to error - NASA